20 results on '"Wong L"'
Search Results
2. P-282 Long-term outcomes after neoadjuvant chemoradiotherapy and R0 resection in ESCC using: A propensity-matched analysis of PF versus CROSS regimen
3. Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
4. Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
5. Prognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting
6. Pembrolizumab (pembro) plus mFOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC): KEYNOTE-651 cohorts B and D
7. 64P - Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
8. Refining staging system for nasopharyngeal carcinoma treated with intensity-modulated radiation therapy
9. 325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
10. 608P - Pembrolizumab (pembro) plus mFOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC): KEYNOTE-651 cohorts B and D
11. 159P - Prognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting
12. Metronomic oral cyclosphosphamide as 3rd line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma
13. Predictive factors for T790M mutation in plasma in patients after progression to 1st line tyrosine-kinase inhibitor (TKI) with or without subsequent lines of TKI or chemotherapy for metastatic epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC)
14. P-339 Total Mesorectal (Chemo) Radiation (TMRT) with integrated Mesorectal boost followed by TME for preoperative therapy for locally advanced rectal cancers
15. 1053PD - Refining staging system for nasopharyngeal carcinoma treated with intensity-modulated radiation therapy
16. 1243P - Predictive factors for T790M mutation in plasma in patients after progression to 1st line tyrosine-kinase inhibitor (TKI) with or without subsequent lines of TKI or chemotherapy for metastatic epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC)
17. 982P - Metronomic oral cyclosphosphamide as 3rd line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma
18. Poster session 6. Phase 1 studies
19. A Phase 1B Study of Brivanib in Combination with 5FU/LV and FOLFIRI in Patients with Advanced or Metastatic Gastro-Intestinal Malignancies
20. 246P Impact of renal impairment on first-line treatment in metastatic urothelial cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.